March 12, 2012 6:32 AM | 1 min read |
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Bank of America raises its rating on Orexigen Therapeutics (NASDAQ: OREX) to Buy with an increased $7 price objective on long-term upside with near term-drivers. Bank of America says, "We are upgrading OREX shares to BUY and increasing our DCF-derived PO from $3.50 to $7 due to attractive valuation (EV only $250mn), potential near-term catalysts, and a favorable long-term outlook for the obesity drug Contrave (expected approval in 2014). If an upcoming FDA advisory meeting (March 28-29) favors pre-approval cardiovascular outcomes studies in obesity drugs, OREX could be best positioned as it already secured an FDA protocol for a CV-based trial that is about to start. Conversely, if the panel supports post-approval CV studies, investors will assign increased value for OREX's phase 3-ready obesity drug Empatic that has similar efficacy/risks as VVUS' Qnexa."OREX closed at $3.70 a share on Friday.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.